ADVFN US – Market Content Editor

  • Impact Fusion Expands Production Capacity With New Proprietary Machinery

    Impact Fusion Expands Production Capacity With New Proprietary Machinery

    Impact Fusion International (USOTC:IFUS) has expanded production capacity at its Napoleonville, Louisiana facility with the installation of a retrofitted Selco/Mosley Badger Double Ram Press, targeting higher output and lower production costs as customer demand and back orders increase. The production expansion is expected to give IFUS initial capacity of 600 bales per day while using…

  • Green Leaf Innovations Plans Luxury Cigar and E-Commerce Expansion Following DURTEQ LOI

    Green Leaf Innovations Plans Luxury Cigar and E-Commerce Expansion Following DURTEQ LOI

    Green Leaf Innovations (USOTC:GRLF) has outlined plans for a luxury cigar and e-commerce expansion that will add a new premium cigar range, branded accessories and a members-only online sales platform as the company seeks to broaden its consumer-products business. The strategy follows Green Leaf Innovations’ recently announced Letter of Intent to acquire a 25% equity…

  • HydroGraph Plans U.S. Redomiciling Vote as Company Aligns Structure With U.S. Growth

    HydroGraph Plans U.S. Redomiciling Vote as Company Aligns Structure With U.S. Growth

    HydroGraph Clean Power (USOTC:HGRAF) will ask shareholders to approve a proposed U.S. redomiciling transaction at a special meeting scheduled for October 29, 2026, as the graphene producer seeks to align its corporate structure with its expanding U.S. operations and shareholder base. The proposed U.S. redomiciling remains subject to shareholder, regulatory, court and other required approvals,…

  • INVO Fertility Q2 Revenue Rises 17% as Clinic-Level Profitability Improves

    INVO Fertility Q2 Revenue Rises 17% as Clinic-Level Profitability Improves

    INVO Fertility (NASDAQ:IVF) reported a 17% increase in second-quarter 2026 revenue to $2.18 million as the first full-quarter contribution from Family Beginnings and growth initiatives across its existing clinics expanded the fertility services platform. Clinic-level Adjusted EBITDA increased to approximately $333,000 from $164,000 in Q1, but consolidated Adjusted EBITDA remained negative at $1.0 million, highlighting…

  • Generation Income Properties Cuts Q2 Loss 76% as Nasdaq Equity Compliance Is Restored

    Generation Income Properties Cuts Q2 Loss 76% as Nasdaq Equity Compliance Is Restored

    Generation Income Properties (NASDAQ:GIPR) narrowed its second-quarter 2026 net loss attributable to common shareholders by 76% year over year and regained compliance with Nasdaq’s stockholders’ equity requirement as asset sales, capital raising and preferred equity restructuring strengthened its balance sheet. The Q2 results show measurable progress in GIPR’s deleveraging strategy, but near-term risks remain, including…

  • EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden

    EyePoint DURAVYU Phase 3 LUGANO Trial Misses Primary Endpoint as Secondary Data Show Reduced Treatment Burden

    EyePoint (NASDAQ:EYPT) reported that its Phase 3 LUGANO trial of DURAVYU in wet age-related macular degeneration did not achieve its primary endpoint in the full dataset, although the company reported positive secondary outcomes and an ad hoc analysis in which DURAVYU was non-inferior to aflibercept. The Phase 3 LUGANO trial result puts added importance on…

  • NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp

    NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp

    NEXGEL (NASDAQ:NXGL) reported second-quarter 2026 revenue of $3.69 million and a net loss of $2.87 million as the healthcare products company worked through a slower-than-expected integration and commercial rollout of its newly formed BioNX Surgical division. The Q2 results highlight a transition period following NEXGEL’s April transaction with Celularity, with supply constraints contributing to a…

  • argenx Phase 3 ALKIVIA Trial Meets Primary Endpoint in Autoimmune Myositis

    argenx Phase 3 ALKIVIA Trial Meets Primary Endpoint in Autoimmune Myositis

    argenx (NASDAQ:ARGX) reported positive topline results from its Phase 3 ALKIVIA trial of VYVGART Hytrulo in adults with autoimmune myositis, with the study meeting its primary endpoint in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population. The Phase 3 ALKIVIA trial produced a statistically significant 15.4-point treatment advantage over placebo in mean Total…

  • IM Cannabis Agrees European Asset Sale as Transaction Targets C$3 Million Equity Improvement

    IM Cannabis Agrees European Asset Sale as Transaction Targets C$3 Million Equity Improvement

    IM Cannabis (NASDAQ:IMCC) has entered into a definitive agreement to sell IMC Holdings and its European-focused assets to Slil.com Holding, a transaction management expects to improve shareholders’ equity by approximately C$3 million while reducing liabilities and simplifying the company’s structure. The proposed European asset sale would leave IM Cannabis focused on its Israeli medical cannabis…

  • Glucotrack Regains Nasdaq Equity Compliance as Strategic Transformation Advances

    Glucotrack Regains Nasdaq Equity Compliance as Strategic Transformation Advances

    Glucotrack (NASDAQ:GCTK) has regained compliance with Nasdaq’s stockholders’ equity requirement, with the Nasdaq Hearings Panel granting the company’s request for continued listing subject to certain conditions. The Nasdaq compliance milestone removes one specific listing issue for Glucotrack as management continues its strategic transformation, although the company said it is still working toward full compliance with…